Loading ......
Transcription factors in the GATA family exhibit conserved type IV zinc finger domains and bind specifically to A/T(GATA)A/G motifs in target gene promoters. These proteins contribute essential functions across embryonic development phases as well as cellular differentiation processes while participating in disease pathogenesis. Six members make up this family (GATA1-6) which splits into two subfamilies according to phylogenetic relationships and tissue expression patterns: GATA1/2/3 and GATA4/5/6. GATA1 functions as an essential transcription factor during blood cell development by directing both the development of red blood cells and the formation of platelet-producing megakaryocytes. GATA4/5/6 subfamily members primarily control cardiovascular development and function. These proteins serve as hub molecules linking normal development and pathological remodeling by dynamically regulating gene regulatory networks.
The zinc finger domains of GATA proteins constitute their functional core, adopting the conserved sequence Cys-X₂-Cys-X₁₇-Cys-X₂-Cys (where X represents variable amino acids and subscripts denote residue counts). C-terminal zinc finger (C-ZnF) mediates sequence-specific DNA binding to A/T(GATA)A/G motifs. N-terminal zinc finger (N-ZnF) enhances regulatory precision through: Stabilization of DNA-protein interactions and Recruitment of cofactors like FOG1 and BRG1-containing chromatin remodeling complexes. Crystallographic studies of GATA3 reveal evolutionary conservation in DNA recognition mechanisms - the Arg329 residue in C-ZnF forms bidentate hydrogen bonds with guanine bases in target DNA. Vertebrate GATA factors universally possess dual zinc fingers, while some invertebrate orthologs retain only the DNA-binding C-ZnF. Additionally, GATA factors remodel chromatin through epigenetic regulatory mechanisms: GATA2 recruits the BRG1 complex to promote chromatin accessibility, while GATA1 mediates spatiotemporal-specific expression by facilitating long-range DNA looping at the β-globin gene cluster.
Figure 1. The six murine members of the GATA family of transcription factors are grouped as GATA1/2/3 and GATA4/5/6 based on expression and similarity
(Source: Tremblay M, et al. 2018)
The GATA family is divided into two subfamilies based on differences in replication timing, cellular localization, structure, and function: The GATA1, GATA2, and GATA3 proteins control blood cell development within the hematopoietic system while GATA4, GATA5, and GATA6 proteins perform crucial functions in mesoderm and endoderm tissues including the heart and gastrointestinal tract to direct gene expression.
The hematopoietic system needs GATA1 to carry out red blood cell and megakaryocyte differentiation processes but losing GATA1 causes severe embryonic anemia together with thrombopoiesis defects. GATA2 mutations cause myelodysplastic syndrome and acute myeloid leukemia precursor states because hematopoietic stem cell self-renewal relies on this gene. The GATA3 protein functions to direct T-lymphocyte development and supports immune responses through Th2 cell polarization. During cardiovascular development, GATA4/5/6 coordinately control cardiac progenitor cell migration and ventricular septal formation. Clinical evidence shows that GATA4 mutations have a strong connection with both atrial septal defects (ASD) and tetralogy of Fallot while heterozygous mutations lead to cardiac primordial fusion failure in mice. GATA-4 functions as a crucial transcriptional factor that controls cardiac precursor cell differentiation throughout heart looping and atrioventricular septation processes during cardiac development. Research indicates that GATA-4 works together with epidermal growth factor (EGF) to influence myocardial differentiation in P19CL6 teratoma cells. Suppressing GATA-4 expression blocks this differentiation process, while its overexpression enhances cardiomyocyte maturation. The anti-apoptotic role of GATA-4 includes cardiomyocyte survival regulation and Bcl-2 gene transcriptional activation. GATA-4 loses significant DNA-binding ability in myocardial infarction cells. The restoration of this activity supports the development of new blood vessels in the heart muscle while initiating protective cellular mechanisms against death and pulling in stem cells which together support the heart's repair process after an infarction.
Figure 2. GATA-2 mutations in human hematologic disorders inform GATA factor mechanisms
(Source: Katsumura KR, et al. 2017)
Liver development is a highly complex dynamic process, primarily involving four stages: endodermal liver specification, liver bud growth, hepatoblast proliferation and differentiation, and liver morphogenesis. Precise spatiotemporal regulation through transcription factor-mediated cell signaling drives the entire process. GATA6 serves as a tissue-specific transcriptional regulator that plays an essential role in cellular proliferation, differentiation, and migration throughout embryonic development. This entity participates in gastrulation as well as mesendoderm specification alongside mesenchymal-to-epithelial transition and organ formation including the liver pancreas and heart. Multiple scientific studies show that GATA6 stands out as one of the essential factors during the initial phase of liver development. GATA6 is critical for endodermal liver lineage specification, participating in the fate transformation of primitive endodermal cells and the initiation of developmental programs in early embryonic development.
GATA and FoxA2 factors are involved in the differentiation of definitive endoderm (DE) into liver-pancreas progenitor cells. Studies show that GATA4/5/6 are central to DE developmental programs, regulating DE development through autonomous and interactive regulatory mechanisms. GATA6 plays a crucial role during the differentiation process of visceral endoderm. The proteins GATA6 and FoxA2 control Wnt6 expression while activating the canonical Wnt signaling pathway to produce extraembryonic endoderm (XEN). Targeted suppression of GATA6 expression in mouse embryos produces XEN developmental defects that result in endodermal differentiation problems and cause early embryonic death. Research results further demonstrate GATA6's crucial regulatory function during endoderm formation.
The functions of GATA transcription factors in tumors demonstrate a dual nature as they operate as tumor suppressors to restrict tumor growth or they promote cancer development via epigenetic changes and signaling network collaboration depending on tissue type and tumor stage as well as molecular context.
The expression of GATA4 in hepatoblastoma cells provides protection against apoptosis caused by doxorubicin treatment. Research demonstrates that GATA4 stimulates cell proliferation and survival in HuH6 cells through miR125b suppression which results in elevated DKK3 expression. The processes of cell proliferation, migration, and invasion are increased through miR125b inhibition or DKK3 overexpression which demonstrates GATA4's indirect promotion of these functions in HuH6 cells.
Promoter methylation of GATA4/5 is common in gastric and colorectal cancers, while the loss of GATA3 accelerates triple-negative breast cancer metastasis by promoting epithelial-to-mesenchymal transition (EMT). Conversely, GATA6 amplification drives abnormal Wnt signaling activation in pancreaticobiliary cancer by inhibiting the Wnt antagonist DKK1. On the other hand, GATA6 can act as a tumor suppressor in pancreatic ductal adenocarcinoma. Research has found that GATA6 directly regulates acinar transcriptional genes, exerting tumor-suppressive effects by promoting cell differentiation, inhibiting inflammatory pathways, and directly suppressing cancer-related pathways (e.g., the epidermal growth factor receptor pathway). Without GATA6, acinar cells undergo acinar-to-ductal metaplasia which increases their sensitivity to KRAS (G12V) mutations and speeds up tumor migration. GATA3 operates as a protective protein in hormone receptor-positive breast cancer by maintaining luminal epithelial cell differentiation. GATA3 creates complexes with estrogen receptor α (ERα) which results in the activation of differentiation-related genes such as FOXA1 and XBP1 while inhibiting EMT. Through its regulation of DNA repair genes BRCA1 and RAD51 GATA3 reduces genomic instability in tumor cells. Research indicates that TNBC patients whose tumors show GATA3 mutations or diminished GATA3 expression demonstrate a marked decrease in responsiveness to PARP inhibitor treatments.
Figure 3. Overview of morphogenic events and key regulators of mouse pancreas development
(Source: Villamayor L, et al. 2020)
The alterations in GATA transcription factor family through genetic mutations or epigenetic dysregulation present strong links to a range of congenital diseases. Multisystem developmental defects frequently occur in these diseases because GATA factors regulate embryonic development through spatiotemporal control functions. HDR syndrome develops from GATA3 haploinsufficiency in genetic disorders since mutations prevent inner ear hair cells and parathyroid progenitor cells from differentiating properly which leads to multiple system abnormalities.
Genetic changes in GATA5 cause its function to diminish either partially or entirely leading to heart disease development. Mutations in GATA5 are associated with familial atrial fibrillation and structural heart defects such as tetralogy of Fallot and ventricular septal defects as well as atrial septal defects and bicuspid aortic valve anomalies. Individuals with one functional copy of GATA2 experience bone marrow failure and immunodeficiency conditions such as MonoMAC which results in low monocytic levels alongside Mycobacterium avium complex infections while Emberger syndrome increases the risk of lymphedema-leukemia. GATA2 maintains the hematopoietic stem cell pool by activating genes like CD34 and HOXB4. Mutant GATA2 (e.g., R398W) loses its cooperative interaction with SMAD1, leading to decreased telomerase activity and premature stem cell exhaustion.
In terms of molecular biomarkers, plasma GATA5 methylation detection has been used for early screening of ovarian cancer, with notable sensitivity in the endometrioid subtype. GATA2 mutation screening guides the management of congenital immunodeficiency, such as monitoring bone marrow failure risk in MonoMAC syndrome patients. Targeted therapeutic strategies include pyridine-based small molecules that inhibit Th2 cell differentiation by blocking GATA3-DNA binding. In gastric cancer models, the combination of vorinostat with trastuzumab increases the tumor regression rate by 40%, involving GATA5-mediated HER2 signaling feedback regulation. The histone acetyltransferase inhibitor TP064 restores chromatin accessibility in GATA2 mutant cells, inducing a 60% increase in CD11b expression, a myeloid differentiation marker, in primary AML cells.
References
| Target | Cat. No. | Product Name | Size | Species | Application | Detection Sample | |
| GATA1 | DEIA-XYA718 | GATA1 ELISA Kit | 96T | Qualitative | Nuclear, cell lysates | Inquiry | |
| DEIA-XYA717 | GATA1 ELISA Kit | 96T | Qualitative | Cultured cells | Inquiry | ||
| DEIA-XYA720 | GATA1 (Phospho-Ser142) ELISA Kit | 96T | Qualitative | Nuclear, cell lysates | Inquiry | ||
| DEIA-XYA722 | GATA1 (Phospho-Ser310) ELISA Kit | 96T | Qualitative | Nuclear, cell lysates | Inquiry | ||
| DEIA-XYA719 | GATA1 (Phospho-Ser142) ELISA Kit | 2 x 96T | Qualitative | Cultured cells | Inquiry | ||
| DEIA-XYA721 | GATA1 (Phospho-Ser310) ELISA Kit | 2 x 96T | Qualitative | Cultured cells | Inquiry | ||
| GATA3 | DEIA-XYA723 | GATA3 ELISA Kit | 96T | Qualitative | Nuclear, cell lysates | Inquiry | |
| GATA4 | DEIA-XYA725 | GATA4 ELISA Kit | 96T | Qualitative | Nuclear, cell lysates | Inquiry | |
| DEIA-XYA724 | GATA4 ELISA Kit | 96T | Qualitative | Cultured cells | Inquiry | ||
| DEIA-XYA726 | GATA4 (Phospho-Ser105) ELISA Kit | 96T | Qualitative | Nuclear, cell lysates | Inquiry | ||
| DEIA-XYA728 | GATA4 (Phospho-Ser262) ELISA Kit | 96T | Qualitative | Nuclear, cell lysates | Inquiry | ||
| GATA5 | DEIA-BJ1043 | Human GATA5(Transcription factor GATA-5) ELISA Kit | 96T | Human | Quantitative | Serum, plasma, tissue homogenates, other biological fluids | Inquiry |
| GATA6 | DEIA-XYA730 | GATA6 ELISA Kit | 96T | Qualitative | Nuclear, cell lysates | Inquiry | |
| DEIA-XYA729 | GATA6 ELISA Kit | 96T | Qualitative | Cultured cells | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| GATA1 | CDBP1338 | Human GATA1 blocking peptide | N/A | Unconjugated | Apuri, BL, ELISA | Inquiry |
| DAG-P1606 | GATA1 peptide | N/A | Unconjugated | ELISA | Inquiry | |
| GATA2 | DAG-P1607 | Human GATA2 peptide | N/A | Unconjugated | ELISA | Inquiry |
| GATA3 | DAG-P0542 | Human GATA3 peptide | N/A | Unconjugated | ELISA | Inquiry |
| CDBP1339 | Human GATA3 blocking peptide | N/A | Unconjugated | Apuri, BL, ELISA | Inquiry | |
| GATA4 | DAG-P1630 | Human GATA4 peptide | N/A | Unconjugated | ELISA | Inquiry |
| GATA5 | CDBP1340 | Human GATA5 blocking peptide | N/A | Unconjugated | Apuri, BL, ELISA | Inquiry |
| GATA6 | DAG-P1597 | Human GATA6 peptide | N/A | Unconjugated | ELISA | Inquiry |
Loading ......